JP2021529834A5 - - Google Patents
Info
- Publication number
- JP2021529834A5 JP2021529834A5 JP2021522935A JP2021522935A JP2021529834A5 JP 2021529834 A5 JP2021529834 A5 JP 2021529834A5 JP 2021522935 A JP2021522935 A JP 2021522935A JP 2021522935 A JP2021522935 A JP 2021522935A JP 2021529834 A5 JP2021529834 A5 JP 2021529834A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- independently selected
- substituted
- group
- compound
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024072451A JP2024102170A (ja) | 2018-07-03 | 2024-04-26 | Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862693878P | 2018-07-03 | 2018-07-03 | |
| US62/693,878 | 2018-07-03 | ||
| US201962861078P | 2019-06-13 | 2019-06-13 | |
| US62/861,078 | 2019-06-13 | ||
| PCT/US2019/040418 WO2020010155A1 (en) | 2018-07-03 | 2019-07-02 | Compounds and compositions for treating conditions associated with sting activity |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024072451A Division JP2024102170A (ja) | 2018-07-03 | 2024-04-26 | Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021529834A JP2021529834A (ja) | 2021-11-04 |
| JP2021529834A5 true JP2021529834A5 (https=) | 2022-07-11 |
| JPWO2020010155A5 JPWO2020010155A5 (https=) | 2022-07-11 |
| JP7482122B2 JP7482122B2 (ja) | 2024-05-13 |
Family
ID=67441663
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021522935A Active JP7482122B2 (ja) | 2018-07-03 | 2019-07-02 | Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物 |
| JP2024072451A Pending JP2024102170A (ja) | 2018-07-03 | 2024-04-26 | Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024072451A Pending JP2024102170A (ja) | 2018-07-03 | 2024-04-26 | Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20210236466A1 (https=) |
| EP (1) | EP3818044A1 (https=) |
| JP (2) | JP7482122B2 (https=) |
| CN (1) | CN112823151B (https=) |
| MA (1) | MA53096A (https=) |
| WO (1) | WO2020010155A1 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112823036B (zh) | 2018-07-03 | 2024-11-08 | 艾福姆德尤股份有限公司 | 用于治疗与sting活性有关的疾病的化合物和组合物 |
| EP3883651A1 (en) * | 2018-11-19 | 2021-09-29 | IFM Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| MA54753A (fr) * | 2019-01-17 | 2021-11-24 | Ifm Due Inc | Composés et compositions pour traiter des états pathologiques associés à une activité de sting |
| TW202043198A (zh) * | 2019-01-17 | 2020-12-01 | 美商Ｉｆｍ Ｄｕｅ有限公司 | 用於治療與sting活性相關之病況的化合物及組合物 |
| IL322315A (en) | 2019-05-14 | 2025-09-01 | Provention Bio Inc | Methods and preparations for preventing type 1 diabetes |
| US20230092163A1 (en) * | 2019-06-14 | 2023-03-23 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| CN114761804A (zh) | 2019-06-21 | 2022-07-15 | 艾福姆德尤股份有限公司 | 治疗癌症的方法 |
| WO2021206158A1 (ja) | 2020-04-10 | 2021-10-14 | 小野薬品工業株式会社 | がん治療方法 |
| KR20230014681A (ko) * | 2020-04-10 | 2023-01-30 | 에이비 사이언스 | 코로나바이러스 질환 2019(covid-19)의 치료를 위한 마시티닙의 용도 |
| AU2021287998B2 (en) | 2020-06-11 | 2026-03-12 | Benaroya Research Institute At Virginia Mason | Methods and compositions for preventing type 1 diabetes |
| WO2022140397A1 (en) | 2020-12-22 | 2022-06-30 | Ifm Due, Inc. | Methods of treating cancer |
| EP4267128A1 (en) | 2020-12-22 | 2023-11-01 | IFM Due, Inc. | Methods of treating cancer |
| EP4267129A1 (en) | 2020-12-22 | 2023-11-01 | IFM Due, Inc. | Methods of treating cancer |
| US20240060982A1 (en) | 2020-12-22 | 2024-02-22 | Ifm Due, Inc. | Methods of treating cancer |
| TW202235073A (zh) | 2021-01-08 | 2022-09-16 | 美商Ｉｆｍ Ｄｕｅ有限公司 | 用於治療與sting活性相關的病狀之化合物及組合物 |
| US12565529B2 (en) | 2021-05-24 | 2026-03-03 | Provention Bio, Inc. | Methods for treating type 1 diabetes |
| UY39892A (es) | 2021-08-10 | 2023-03-31 | Novartis Pharma Ag | Compuestos y composiciones para tratar afecciones asociadas con la actividad de STING |
| CN116789641A (zh) * | 2022-03-17 | 2023-09-22 | 中国科学院上海药物研究所 | 二氢异喹啉类化合物及其医药用途 |
| CN114712365B (zh) * | 2022-06-07 | 2022-08-23 | 山东绿叶制药有限公司 | Trk抑制剂在制备治疗迟发性运动障碍药物中的应用 |
| WO2024064358A1 (en) | 2022-09-23 | 2024-03-28 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| CN115960047B (zh) * | 2023-01-10 | 2025-04-15 | 中国药科大学 | 一种3-苯基-1h-吡唑类化合物及其用途 |
| WO2025111251A1 (en) * | 2023-11-20 | 2025-05-30 | Exelixis, Inc. | Compounds that inhibit polo-like kinase 4 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3563985A (en) * | 1967-12-15 | 1971-02-16 | Fmc Corp | Process for preparing certain acylaminoisothiazoles |
| US4230713A (en) * | 1979-01-19 | 1980-10-28 | Ici Americas Inc. | Heterocyclic tetrahydro-1-alkyl-4-oxo-1H-imidazol-2-ylidene urea and phenyl esters of tetrahydro-1-alkyl-4-oxo-1H-imidazol-2-ylidene carbamic acid compounds |
| DE3332270A1 (de) * | 1983-09-07 | 1985-03-21 | Bayer Ag, 5090 Leverkusen | Herbizide mittel enthaltend metribuzin in kombination mit 1,4-disubstituierten pyrazol-derivaten |
| US5849769A (en) * | 1994-08-24 | 1998-12-15 | Medivir Ab | N-arylalkyl-N-heteroarylurea and guandine compounds and methods of treating HIV infection |
| AU7726898A (en) * | 1997-05-22 | 1998-12-11 | G.D. Searle & Co. | Pyrazole derivatives as p38 kinase inhibitors |
| ID26328A (id) * | 1997-12-22 | 2000-12-14 | Bayer Ag | Penghambat raf kinase menggunakan urea heterosiklik tersubstitusi aril dan heteroaril |
| PY0117895A (es) * | 2000-07-31 | 2003-11-03 | Pfizer Prod Inc | Derivados de imidazol |
| UA76977C2 (en) * | 2001-03-02 | 2006-10-16 | Icos Corp | Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers |
| JP5039268B2 (ja) * | 2001-10-26 | 2012-10-03 | アベンティス・ファーマスーティカルズ・インコーポレイテツド | ベンゾイミダゾールおよび類縁体および蛋白キナーゼ阻害剤としてのその使用 |
| US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| DK1618092T3 (da) * | 2003-05-01 | 2011-01-31 | Bristol Myers Squibb Co | Aryl-substituerede pyrazol-amidforbindelser, der er anvendelige som kinasehæmmere |
| TWI372050B (en) * | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
| JP2005104968A (ja) * | 2003-09-12 | 2005-04-21 | Sumitomo Chemical Co Ltd | フェニルピラゾール化合物及びその用途 |
| US20050192314A1 (en) * | 2003-11-13 | 2005-09-01 | Ambit Biosciences Corporation | Urea derivatives as C-kit modulators |
| US20100160324A1 (en) * | 2004-12-30 | 2010-06-24 | Astex Therapeutics Limited | Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases |
| EP1801098A1 (en) * | 2005-12-16 | 2007-06-27 | Merck Sante | 2-Adamantylurea derivatives as selective 11B-HSD1 inhibitors |
| WO2012075380A1 (en) | 2010-12-03 | 2012-06-07 | The Trustees Of The University Of Pennsylvania | Tip60 inhibitors |
| US9169248B2 (en) * | 2012-12-21 | 2015-10-27 | Chemocentryx, Inc. | Diazole amides |
| RS59500B1 (sr) | 2013-05-18 | 2019-12-31 | Aduro Biotech Inc | Sastavi i metode za aktiviranje signaliziranja koje je zavisno od „stimulatora gena za interferon“ |
| WO2015039334A1 (en) * | 2013-09-22 | 2015-03-26 | Merck Sharp & Dohme Corp. | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
| CN109394752A (zh) | 2013-10-21 | 2019-03-01 | 德雷克塞尔大学 | 治疗慢性乙型肝炎病毒感染的sting激动剂的用途 |
| CN103739550B (zh) * | 2014-01-02 | 2016-06-01 | 中国药科大学 | 2,3-二甲基-6-脲-2h-吲唑类化合物及其制备方法与应用 |
| JP2019510802A (ja) * | 2016-04-07 | 2019-04-18 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | タンパク質調節物質として有用な複素環アミド |
| CN106986860A (zh) * | 2017-05-19 | 2017-07-28 | 南京大学 | 一类含酰胺键的吡唑类抗肿瘤化合物的设计、合成 |
| CN107417478B (zh) * | 2017-06-05 | 2020-05-05 | 南京师范大学 | 一种催化氧化羰基化合成不对称二取代脲的方法 |
| JP2020524718A (ja) * | 2017-06-22 | 2020-08-20 | キュラデブ・ファーマ・リミテッドＣｕｒａｄｅｖ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ | ヒトｓｔｉｎｇの複素環式小分子調節因子 |
| EP3790500B1 (en) * | 2018-05-10 | 2022-07-06 | Koninklijke Philips N.V. | Methods and systems for adjusting behavior of oral care device based on status of oral cavity |
-
2019
- 2019-07-02 US US17/257,225 patent/US20210236466A1/en not_active Abandoned
- 2019-07-02 WO PCT/US2019/040418 patent/WO2020010155A1/en not_active Ceased
- 2019-07-02 EP EP19745422.6A patent/EP3818044A1/en active Pending
- 2019-07-02 JP JP2021522935A patent/JP7482122B2/ja active Active
- 2019-07-02 MA MA053096A patent/MA53096A/fr unknown
- 2019-07-02 CN CN201980057351.7A patent/CN112823151B/zh active Active
-
2024
- 2024-04-26 JP JP2024072451A patent/JP2024102170A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021529834A5 (https=) | ||
| JP2021529833A5 (https=) | ||
| JP6839772B2 (ja) | 抗ＰＤ−１抗体との組み合わせのための抗Ｔｉｍ−３抗体 | |
| JP6839761B2 (ja) | 抗ＰＤ−Ｌ１抗体との組み合わせのための抗Ｔｉｍ−３抗体 | |
| JP7461741B2 (ja) | 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン | |
| JP6779299B2 (ja) | 抗ｐｄ−ｌ１抗体およびその使用 | |
| JPWO2020010155A5 (https=) | ||
| JPWO2020010092A5 (https=) | ||
| JP7046973B2 (ja) | 抗ｏｘ４０抗体およびその使用 | |
| WO2017016497A1 (en) | Anti-pd-1 antibodies and uses thereof | |
| CN111094348B (zh) | 双特异性抗pd1-抗tim3抗体 | |
| WO2013082463A2 (en) | Assays, antibodies, immunogens and compositions related to 5-fu | |
| CN119136840A (zh) | 喜树碱类衍生物及配体-药物偶联物 | |
| JPWO2021138419A5 (https=) | ||
| JPWO2020106736A5 (https=) | ||
| JP2019522624A (ja) | 抗ｐｄ−ｌ１−抗ｔｉｍ−３二重特異性抗体 | |
| JP7059389B2 (ja) | 抗ｐｄ－１抗体との組み合わせのための抗ｃｄ１３７抗体 | |
| JPWO2020150439A5 (https=) | ||
| JP7059388B2 (ja) | 抗ｐｄ－ｌ１抗体との組み合わせのための抗ｃｄ１３７抗体 | |
| TWI888704B (zh) | 抗ｃｄ７３之抗體及其應用 | |
| WO2024204629A1 (ja) | 抗ｃｄ２５抗体及び抗ｃｄ２５抗体－薬物コンジュゲート | |
| RU2021126926A (ru) | Антитела, которые связывают опухолевую ткань, для диагностики и лечения | |
| NZ741686B2 (en) | Combination therapy using inhibitors of human growth and differentiation factor 15 (gdf-15) and immune checkpoint blockers | |
| NZ741686A (en) | Combination therapy using inhibitors of human growth and differentiation factor 15 (gdf-15) and immune checkpoint blockers |